Cargando…
Challenges of CAR- and TCR-T cell–based therapy for chronic infections
While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201928/ https://www.ncbi.nlm.nih.gov/pubmed/32163104 http://dx.doi.org/10.1084/jem.20191663 |
| _version_ | 1783529635445735424 |
|---|---|
| author | Bertoletti, Antonio Tan, Anthony Tanoto |
| author_facet | Bertoletti, Antonio Tan, Anthony Tanoto |
| author_sort | Bertoletti, Antonio |
| collection | PubMed |
| description | While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections? |
| format | Online Article Text |
| id | pubmed-7201928 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Rockefeller University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72019282020-11-04 Challenges of CAR- and TCR-T cell–based therapy for chronic infections Bertoletti, Antonio Tan, Anthony Tanoto J Exp Med Viewpoint While therapy with T cells engineered with a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) is revolutionizing cancer treatment, its adoption in infectious diseases has been met with considerable resistance. Can we find its value for the cure of infections? Rockefeller University Press 2020-03-12 /pmc/articles/PMC7201928/ /pubmed/32163104 http://dx.doi.org/10.1084/jem.20191663 Text en © 2020 Bertoletti and Tan http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
| spellingShingle | Viewpoint Bertoletti, Antonio Tan, Anthony Tanoto Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title | Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title_full | Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title_fullStr | Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title_full_unstemmed | Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title_short | Challenges of CAR- and TCR-T cell–based therapy for chronic infections |
| title_sort | challenges of car- and tcr-t cell–based therapy for chronic infections |
| topic | Viewpoint |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201928/ https://www.ncbi.nlm.nih.gov/pubmed/32163104 http://dx.doi.org/10.1084/jem.20191663 |
| work_keys_str_mv | AT bertolettiantonio challengesofcarandtcrtcellbasedtherapyforchronicinfections AT tananthonytanoto challengesofcarandtcrtcellbasedtherapyforchronicinfections |